التفاصيل البيبلوغرافية
| العنوان: |
The Role of TP53 Mutations in EGFR -Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. |
| المؤلفون: |
Canale, Matteo, Andrikou, Kalliopi, Priano, Ilaria, Cravero, Paola, Pasini, Luigi, Urbini, Milena, Delmonte, Angelo, Crinò, Lucio, Bronte, Giuseppe, Ulivi, Paola |
| المصدر: |
Cancers; Mar2022, Vol. 14 Issue 5, p1143, 1p |
| مصطلحات موضوعية: |
LUNG cancer & genetics, LUNG cancer prognosis, THERAPEUTIC use of antineoplastic agents, LUNG cancer, GENETIC mutation, EPIDERMAL growth factor receptors, PROTEIN-tyrosine kinase inhibitors, DNA-binding proteins, TUMOR markers, DRUG resistance in cancer cells |
| مستخلص: |
Simple Summary: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment discontinuation and disease progression. Tumor protein 53 (TP53) mutations are the most common mutations in NSCLC, and several reports highlighted a role for these mutations in influencing prognosis and responsiveness to EGFR targeted therapy. In this review, we discuss the emerging data about the role of TP53 in predicting EGFR mutated NSCLC patients' prognosis and responsiveness to targeted therapy. Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder